Summary
Financial overview
· Net sales amounted to
· Loss for the period was
· Loss per share, before and after dilution, was
· On
Significant events during the period
· Top line results from the company's pivotal phase 2 study HORIZON were presented and showed a 26% Overall Response Rate (ORR) of melflufen in triple-class refractory multiple myeloma patients
· The Lancet Haematology published detailed results from
·
· The company strengthened its management team with several new senior executives
Significant events after the reporting period
· In May,
· The enrollment in the pivotal phase 3 study OCEAN was successfully completed in May including 450 patients from more than 100 hospitals around the world
Financial overview of the group
[]
2020 2019[1)] 2019
Jan -
Net sales - - -
Operating loss -296,876 -133,812 -739,392
Loss before tax -297,327 -133,946 -739,920
Loss for the period -297,329 -134,077 -740,705
Earnings per share before -5.37 -2.82 -14.33
and after
dilution (SEK)
Cash flow from operating -312,841 -142,821 -690,566
activities
Cash and cash equivalents 617,786 747,471 926,186
at the end of the period
Research & development 72% 80% 74%
costs/operating expenses
%
1) Earlier periods have been adjusted to reflect correction of errors, see note 6.
Conference call for investors, analysts and the media
The Interim Report Q1 2020 and an operational update will be presented by CEO
Phone numbers for participants from:
Financial calendar
Annual General Meeting
Interim Report Q2, 2020:
Interim Report Q3, 2020:
For further information
E-mail: jakob.lindberg@oncopeptides.com
Telephone: +46 (0)8 615 20 40
E-mail: rein.piir@oncopeptides.com
Telephone: +46 (0)70 853 72 92
This information is information that
About
For more information please visit www.oncopeptides.com.
https://news.cision.com/oncopeptides-ab/r/interim-report-q1-2020,c3119486
https://mb.cision.com/Main/15404/3119486/1253315.pdf
https://mb.cision.com/Public/15404/3119486/9b31ac3c6188b047.pdf
(c) 2020 Cision. All rights reserved., source